Comprehensive Management of Von Hippel-Lindau Disease: Genetic and Oncological Perspectives
Tracking # 20-1241294
Course overview
Von Hippel-Lindau disease (VHL) is an inherited disorder that predisposes individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, requiring the involvement of genetic counselors and clinicians across the interprofessional team for optimal management. In this enduring webinar, gain expert perspectives from Dr. Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center. Start the activity now.
Subject areas
This course counts toward the state boards and subject areas below.
Arkansas State Board of Nursing
Certified Nurse Practitioner
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
Registered Nurse Practitioner
District of Columbia Board of Nursing
Clinical Nurse Specialist
Licensed Practical Nurse
Nurse Practitioner
Registered Nurse
Florida Board of Nursing - Certified Nursing Assistants
Certified Nursing Assistant
Georgia Board of Nursing
Licensed Practical Nurse
Registered Professional Nurse
Kansas State Board of Nursing
Clinical Nurse Specialist
Licensed Practical Nurse
Nurse Practitioner
Registered Nurse
New Hampshire Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
New Mexico Board of Nursing
Certified Nurse Practitioner
Certified Registered Nurse Anesthetist
Clinical Nurse Specialist
Licensed Practical Nurse
Registered Nurse
North Dakota Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
South Carolina Board of Nursing
Advanced Practice Registered Nurse
Licensed Practical Nurse
Registered Nurse
Wyoming Board of Nursing
Certified Nurse Practitioner
Certified Nurse Specialist
Certified Nursing Assistant
Certified Registered Nurse Anesthetist
Licensed Practical Nurse
Registered Nurse
Disclosure statements
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Eric Jonasch, MD, discloses that he has served as a consultant for Aveo, Eisai, Exelixis, GlaxoSmithKline, Ipsen, Novartis, Merck, NiKang, Takeda, and Telix; and that he has received grants/research support from Aveo, AbbVie, Bristol Myers Squibb, Corvus, Merck, NiKang, and Telix.
i3 Health has mitigated all relevant financial relationships.